Cargando…

Radiotherapy treatment modification for prostate cancer patients based on PSMA-PET/CT

BACKGROUND: Prostate cancer is the most common cancer among men, and its diagnosis and treatment are improving. Our study evaluated how PSMA-PET/CT prior to treatment planning might improve the optimal management of prostate cancer radiotherapy. METHODS: This retrospective pilot study included 43 pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Karagiannis, Vasileios, Wichmann, Viktor, Saarinen, Juha, Eigeliene, Natalja, Andersen, Heidi, Jekunen, Antti
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800353/ https://www.ncbi.nlm.nih.gov/pubmed/35093103 http://dx.doi.org/10.1186/s13014-022-01989-5

Ejemplares similares

Gene-Guided Treatment Decision-Making in Non-Small Cell Lung Cancer – A Systematic Review
por: Saarenheimo, Jatta, et al.
Publicado: (2021)

Metastatic Rectal Carcinoma with Long-Term Remission due to Modern Multimodality Treatment
por: Eigeliene, Natalja, et al.
Publicado: (2021)

Current challenges in applying gene-driven therapies in clinical lung cancer practice
por: Saarenheimo, Jatta, et al.
Publicado: (2021)

The Value of Liquid Biopsies for Guiding Therapy Decisions in Non-small Cell Lung Cancer
por: Saarenheimo, Jatta, et al.
Publicado: (2019)

Re: The role of (68)Ga-PSMA-PET/CT in radiotherapy planning in prostate cancer
por: Cihan, Yasemin Benderli
Publicado: (2019)

PSMA PET-CT in the Diagnosis and Staging of Prostate Cancer
por: Combes, Alexander D., et al.
Publicado: (2022)

Comparison of (68)Ga-PSMA PET/CT with fluoride PET/CT for detection of bone metastatic disease in prostate cancer
por: Regula, Naresh, et al.
Publicado: (2022)

PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml
por: Solomonidou, Nantia, et al.
Publicado: (2023)

68Ga-PSMA-PET/CT-based radiosurgery and stereotactic body radiotherapy for oligometastatic prostate cancer
por: Kalinauskaite, Goda, et al.
Publicado: (2020)

Irreversible electroporation for prostate cancer using PSMA PET-CT
por: Shin, Dongho, et al.
Publicado: (2023)

Comparison of (68)Ga-PSMA-11 PET/CT with (11)C-acetate PET/CT in re-staging of prostate cancer relapse
por: Regula, Naresh, et al.
Publicado: (2020)

Ga-68-PSMA PET/CT ? or PET/MRI ?, Mp-MRI ? in diagnosis and radiotherapy planning in a patient with prostate cancer
por: Cihan, Yasemin Benderli
Publicado: (2020)

Meta-analysis of (18) F-PSMA-1007 PET/CT, (18) F-FDG PET/CT, and (68)Ga-PSMA PET/CT in diagnostic efficacy of prostate Cancer
por: Yu, Wenxiao, et al.
Publicado: (2023)

The Utility of 68Ga-PSMA PET/CT in Decisions Regarding Administering Salvage Radiotherapy to Men with Prostate Cancer
por: Ben Shimol, Jennifer, et al.
Publicado: (2022)

Can PSMA PET/CT help in dose-tailoring in post-prostatectomy radiotherapy?
por: Champion, Ambroise, et al.
Publicado: (2023)

PSMA PET/CT in Castration-Resistant Prostate Cancer: Myth or Reality?
por: Urso, Luca, et al.
Publicado: (2023)

Primary Staging of Prostate Cancer Patients with [(18)F]PSMA-1007 PET/CT Compared with [(68)Ga]Ga-PSMA-11 PET/CT
por: Hoffmann, Manuela A., et al.
Publicado: (2022)

Comparison of (68)Ga-PSMA PET/CT and (18)F-PSMA PET/CT of a Patient with Prostate Cancer Recurrence on Urinary Bladder Wall
por: Soydal, Çiğdem, et al.
Publicado: (2023)

Direct comparison of (99m)Tc-PSMA SPECT/CT and (68)Ga-PSMA PET/CT in patients with prostate cancer
por: Albalooshi, Batool, et al.
Publicado: (2020)

PSMA-11-PET/CT versus choline-PET/CT to guide stereotactic ablative radiotherapy for androgen deprivation therapy deferral in patients with oligometastatic prostate cancer
por: Deijen, Charlotte L., et al.
Publicado: (2021)

Randomized prospective phase III trial of (68)Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]
por: Calais, Jeremie, et al.
Publicado: (2019)

The influence of digital PET/CT on diagnostic certainty and interrater reliability in [(68)Ga]Ga-PSMA-11 PET/CT for recurrent prostate cancer
por: Alberts, Ian, et al.
Publicado: (2021)

Efficacy of PSMA PET-Guided Radiotherapy for Oligometastatic Castrate-Resistant Prostate Cancer
por: Henkenberens, Christoph, et al.
Publicado: (2021)

Correction to: Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]
por: Calais, Jeremie, et al.
Publicado: (2019)

Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer
por: Lenzo, Nat P., et al.
Publicado: (2018)

Specificity of (68)Ga-PSMA PET/CT for Prostate Cancer - Myths and Reality
por: Sasikumar, Arun
Publicado: (2017)

Clinical Utility of Gallium-68 PSMA PET/CT Scan for Prostate Cancer
por: Kallur, Kumaraswamy G, et al.
Publicado: (2017)

PSMA PET/CT to evaluate response to SBRT for prostate cancer bone metastases
por: Sadetski, Igor, et al.
Publicado: (2021)

Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer
por: Fanti, Stefano, et al.
Publicado: (2020)

Detection efficacy of [(89)Zr]Zr-PSMA-617 PET/CT in [(68)Ga]Ga-PSMA-11 PET/CT-negative biochemical recurrence of prostate cancer
por: Rosar, Florian, et al.
Publicado: (2023)

PSMA-PET/CT-Based Stereotactic Body Radiotherapy (SBRT) in the Treatment of Uncomplicated Non-Spinal Bone Oligometastases from Prostate Cancer
por: Pastorello, Edoardo, et al.
Publicado: (2023)

PSMA PET in Imaging Prostate Cancer
por: Tsechelidis, Ioannis, et al.
Publicado: (2022)

A Multi-Institutional Analysis of Prostate Cancer Patients With or Without 68Ga-PSMA PET/CT Prior to Salvage Radiotherapy of the Prostatic Fossa
por: Schmidt-Hegemann, Nina-Sophie, et al.
Publicado: (2021)

Outcome of patients with biochemical recurrence of prostate cancer after PSMA PET/CT-directed radiotherapy or surgery without systemic therapy
por: Harsini, Sara, et al.
Publicado: (2023)

Single-Center Comparison of [(64)Cu]-DOTAGA-PSMA and [(18)F]-PSMA PET–CT for Imaging Prostate Cancer
por: Mirzaei, Siroos, et al.
Publicado: (2021)

(68)Ga-PSMA PET-CT and PSMA score affecting therapeutic decision-making in high-risk prostatic carcinoma
por: Yasmin, Tahira, et al.
Publicado: (2023)

Diagnostic efficiency of hybrid imaging using PSMA ligands, PET/CT, PET/MRI and MRI in identifying malignant prostate lesions
por: Scobioala, Sergiu, et al.
Publicado: (2021)

All that Glitters on PSMA is Not a Lesion: An Unusual Artifact on PSMA PET/CT
por: Dev, Indraja D., et al.
Publicado: (2021)

Targeted Prostate Biopsy Using (68)Gallium PSMA-PET/CT for Image Guidance
por: Simopoulos, Demetrios N., et al.
Publicado: (2017)

(68)Ga-PSMA-PET/CT for the evaluation of liver metastases in patients with prostate cancer
por: Damjanovic, Jonathan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_8bpuf65g5761jh26lma202v10q